About the Company
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery (Vector-Adjuvant-Antigen Standardized Technology known as VAAST) include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc. Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. The company has achieved significant milestones in its vaccine development, including completing Phase 1 trials for its COVID-19 vaccine candidate and embarking on Phase 2 studies. Vaxart’s vaccines are designed to elicit not only systemic immune responses but also mucosal and T cell responses, which may enhance protection against specific diseases and offer potential benefits for certain cancers and chronic viral infections. The tablet form of these vaccines represents a significant advancement in vaccine administration, potentially improving patient acceptance and resolving distribution challenges.
Exchange
OTC
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Vaxart, Inc.
Vaxart, Inc. (NASDAQ:VXRT) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 13, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.07, ...
Vaxart Inc (VXRT) Q2 2025 Earnings Call Highlights: Revenue Surge Amidst Operational Challenges
Vaxart Inc (VXRT) reports a significant revenue increase but faces hurdles with trial suspensions and NASDAQ compliance ...
Vaxart, Inc. Announces Results from 2025 Annual Meeting of ... - Nasdaq
Quiver AI Summary Vaxart, Inc., a biotechnology company specializing in oral recombinant vaccines, held its Annual Meeting of Stockholders virtually on June 13, 2025.
Vaxart to Host Virtual Stockholder Fireside Chat on Wednesday, August 20 to Discuss Reverse Stock Split Proposal
ISS and Glass Lewis, leading independent proxy advisory firms, support reverse stock split proposal - - Webcast to begin at 4:30 p.m. ET / 1:30 p.m. PT - SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 ...
VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates
VAXART, INC. (VXRT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.09 per share a year ago. These figures are ...
Vaxart, Inc. Encourages Stockholders to Approve Reverse Stock Split ...
Vaxart, Inc. has urged its stockholders to vote in favor of a reverse stock split proposal during the upcoming Annual Meeting on May 21, 2025, to avoid being delisted from Nasdaq due to its ...
OTC Markets Group Welcomes Vaxart, Inc. to OTCQX
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCM) (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vaxart ...
Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the ...
Wouter Latour, M.D., Chief Executive Officer of Vaxart, Inc., said, “The amended terms reflect our commitment to completing the transaction with Aviragen.
Vaxart, Inc. Reports Inducement Grants Under Nasdaq ... - Morningstar
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) Provided by GlobeNewswire May 20, 2025, 2:00:17 PM ...
VXRT | Vaxart Inc. Profile | MarketWatch
Vaxart Inc. 170 Harbor Way Suite 300 South San Francisco, California 94080 Phone1 650 550-3500 IndustryBiotechnology SectorHealth Care/Life Sciences Fiscal Year-end12/2025 Revenue$28.7M Net Income ...
Vaxart, Inc.: Vaxart CEO Issues Letter to Stockholders
Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025 - SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc.
Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common ...
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (VXRT) today announced the pricing of its underwritten public offering of 16,000,000 shares of its common stock, for ...
Similar Companies
Loading the latest forecasts...